BioSpace News Archive

LEXINGTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Recent Business and Financial Performance Highlights Achieved fourth quarter total revenue of $3.1 million and product revenue of $1.6 million, representing increases of 71% and 18% respectively, compared to the prior year period

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ multimodality multiplex Extended Serological Disease Screening (SDS) Microarray confirming feasibility of the MosaiQ system to address the needs of the Company’s donor center customers for serological disease screening.

Axovant Gene Therapies Ltd. (Nasdaq: AXGT) (“Axovant”) today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to purchase 2,600,000 additional common shares, at a price to the public of $3.75 per share.

SANTA MONICA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the market close, and will host a corporate update conference call and webcast on Wednesday, March 4, at 4:30 p.m. Eastern Time. Conference Call Details: Wed

EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report fourth quarter and full year 2019 financial results on Wednesday, March 11, 2020, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, March 11, 2019 at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through

Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year 2019 financial results and provided a corporate update.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019.

ALACHUA, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. Fourth Quarter 2019 Financial Results and Business Highlights Net sales were $28.1 million during the quarter, an increase of 20% compared to fourth quarter 2018 revenue of $23.4 million. G

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $257.9 million for the quarter ended December 31, 2019, an increase of 10.6% over revenue of $233.2 million for the quarter ended December 31, 2018.

Alkermes plc announced that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m. ET from Boston.